Literature DB >> 29724418

ACR Appropriateness Criteria® Pretreatment Staging of Muscle-Invasive Bladder Cancer.

Christian B van der Pol1, V Anik Sahni2, Steven C Eberhardt3, Aytekin Oto4, Oguz Akin5, Lauren F Alexander6, Brian C Allen7, Fergus V Coakley8, Adam T Froemming9, Pat F Fulgham10, Keyanoosh Hosseinzadeh11, Jodi K Maranchie12, Rekha N Mody13, Nicola Schieda14, David M Schuster6, Aradhana M Venkatesan15, Carolyn L Wang16, Mark E Lockhart17.   

Abstract

Muscle-invasive bladder cancer (MIBC) has a tendency toward urothelial multifocality and is at risk for local and distant spread, most commonly to the lymph nodes, bone, lung, liver, and peritoneum. Pretreatment staging of MIBC should include imaging of the urothelial upper tract for synchronous lesions; imaging of the chest, abdomen, and pelvis for metastases; and MRI pelvis for local staging. CT abdomen and pelvis without and with contrast (CT urogram) is recommended to assess the urothelium and abdominopelvic organs. Pelvic MRI can improve local bladder staging accuracy. Chest imaging is also recommended with chest radiograph usually being adequate. FDG-PET/CT may be appropriate to identify nodal and metastatic disease. Chest CT may be useful in high-risk patients and those with findings on chest radiograph. Nonurogram CT and MRI of the abdomen and pelvis are usually not appropriate, and neither is radiographic intravenous urography, Tc-99m whole body bone scan, nor bladder ultrasound for pretreatment staging of MIBC. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
Copyright © 2018 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AUC; Appropriate Use Criteria; Appropriateness Criteria; Bladder cancer; CT; MRI; Muscle-invasive bladder cancer; Staging; Urothelial carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29724418     DOI: 10.1016/j.jacr.2018.03.020

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  11 in total

1.  Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center.

Authors:  Giovanni Barchetti; Giuseppe Simone; Isabella Ceravolo; Vincenzo Salvo; Riccardo Campa; Francesco Del Giudice; Ettore De Berardinis; Dorelsa Buccilli; Carlo Catalano; Michele Gallucci; James W F Catto; Valeria Panebianco
Journal:  Eur Radiol       Date:  2019-03-18       Impact factor: 5.315

Review 2.  MRI of Tumors and Tumor Mimics in the Female Pelvis: Anatomic Pelvic Space-based Approach.

Authors:  Stephanie Nougaret; Ines Nikolovski; Viktoriya Paroder; Hebert A Vargas; Evis Sala; Sebastien Carrere; Raphael Tetreau; Christine Hoeffel; Rosemarie Forstner; Yulia Lakhman
Journal:  Radiographics       Date:  2019 Jul-Aug       Impact factor: 5.333

3.  Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography.

Authors:  Martijn P A Starmans; Li Shen Ho; Fokko Smits; Nick Beije; Inge de Kruijff; Joep J de Jong; Diederik M Somford; Egbert R Boevé; Ed Te Slaa; Evelyne C C Cauberg; Sjoerd Klaver; Antoine G van der Heijden; Carl J Wijburg; Addy C M van de Luijtgaarden; Harm H E van Melick; Ella Cauffman; Peter de Vries; Rens Jacobs; Wiro J Niessen; Jacob J Visser; Stefan Klein; Joost L Boormans; Astrid A M van der Veldt
Journal:  J Pers Med       Date:  2022-04-30

Review 4.  What a difference a delay makes! CT urogram: a pictorial essay.

Authors:  Abraham Noorbakhsh; Lejla Aganovic; Noushin Vahdat; Soudabeh Fazeli; Romy Chung; Fiona Cassidy
Journal:  Abdom Radiol (NY)       Date:  2019-12

Review 5.  Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder.

Authors:  Chanan Reitblat; Joaquim Bellmunt; Boris Gershman
Journal:  Curr Oncol Rep       Date:  2021-02-09       Impact factor: 5.075

Review 6.  The Role of Imaging in Bladder Cancer Diagnosis and Staging.

Authors:  Samuel J Galgano; Kristin K Porter; Constantine Burgan; Soroush Rais-Bahrami
Journal:  Diagnostics (Basel)       Date:  2020-09-16

Review 7.  The Role of Molecular Imaging in a Muscle-Invasive Bladder Cancer Patient: A Narrative Review in the Era of Multimodality Treatment.

Authors:  Vincenzo Cuccurullo; Giuseppe Danilo Di Stasio; Francesco Manti; Pierpaolo Arcuri; Rocco Damiano; Giuseppe Lucio Cascini
Journal:  Diagnostics (Basel)       Date:  2021-05-11

Review 8.  PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review.

Authors:  Christophe Van de Wiele; Mike Sathekge; Bart de Spiegeleer; Pieter Jan de Jonghe; Laurence Beels; Alex Maes
Journal:  Int J Mol Sci       Date:  2019-10-02       Impact factor: 5.923

Review 9.  Imaging of Bladder Cancer: Standard Applications and Future Trends.

Authors:  Rasha Taha Abouelkheir; Abdalla Abdelhamid; Mohamed Abou El-Ghar; Tarek El-Diasty
Journal:  Medicina (Kaunas)       Date:  2021-03-01       Impact factor: 2.430

Review 10.  Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group.

Authors:  Antonio Gómez Caamaño; Ana M García Vicente; Pablo Maroto; Alfredo Rodríguez Antolín; Julián Sanz; María Almudena Vera González; Miguel Ángel Climent
Journal:  Curr Oncol       Date:  2021-12-03       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.